间质-上皮转化在肿瘤转移中的作用

肿瘤转移是一个多步骤、多因素参与的复杂过程,是目前临床上绝大多数肿瘤患者的致死因素.上皮-间质转化(epithelial-mesenchymal transition, EMT)过程已被证实可促使肿瘤细胞发生转移.近年来许多研究表明,间质-上皮转化(mesenchymal-epithelial transition, MET)即EMT的逆过程,与肿瘤也密切相关,特别是肿瘤转移即形成继发性的肿瘤转移灶.深入研究肿瘤MET有望为肿瘤转移的预防和诊治提供新思路.     

EMT参与肿瘤侵袭转移的研究进展

在癌症类型中,上皮癌占绝大多数。从良性腺瘤过渡到恶性癌和转移期间,上皮肿瘤细胞获得去分化、迁移和入侵行为,同时上皮-间质转化（epithelial-mesenchymal transition EMT）伴随着显著的细胞形态学变化、细胞与细胞间及细胞与基质之间的粘附性丢失及重塑、并获得迁徙和侵袭能力。正如完全分化的上皮细胞转换成低分化、迁移和侵入性间质细胞,其涉及到一个高度的细胞可塑性、大量不同的基因和表观遗传学改变,因此EMT本身是一个多阶段的过程。该综述的目的是系统地总结EMT分子机制及EMT与肿瘤关系的最新进展。     

EMT参与肿瘤侵袭转移的研究进展

在癌症类型中,上皮癌占绝大多数。从良性腺瘤过渡到恶性癌和转移期间,上皮肿瘤细胞获得去分化、迁移和入侵行为,同时上皮-间质转化(epithelial-mesenchymal transition EMT)伴随着显著的细胞形态学变化、细胞与细胞间及细胞与基质之间的粘附性丢失及重塑、并获得迁徙和侵袭能力。正如完全分化的上皮细胞转换成低分化、迁移和侵入性间质细胞,其涉及到一个高度的细胞可塑性、大量不同的基因和表观遗传学改变,因此EMT本身是一个多阶段的过程。该综述的目的是系统地总结EMT分子机制及EMT与肿瘤关系的最新进展。     

微RNA通过调节上皮间质转化影响肿瘤转移

肿瘤细胞向远处转移受多因素调控, 涉及多个基因, 需要经历一系列连续的、可选择的级联事件。上皮间质转化(Epithelial-mesenchymal transition, EMT)是肿瘤细胞转移中的关键步骤, 但肿瘤发生 EMT的机制至今尚不完全明确。微RNA (MicroRNA, miRNA)是一类内源性、非编码小分子RNA, 可在转录后水平负调控EMT相关基因的表达, 在肿瘤转移中发挥重要作用。文章主要就EMT与肿瘤转移的关系、影响EMT的转录因子, 以及miRNA通过靶向EMT相关的转录因子影响肿瘤转移等方面进行了综述。     

去泛素化酶在肿瘤上皮间质转化中的作用

肿瘤的侵袭和转移是加剧肿瘤恶化的主要原因,也是导致患者预后不良的根本原因。近年来大量研究发现,大部分肿瘤的转移都依赖于上皮间质转化(epithelial-mesenchymal transition, EMT)的发生,此外EMT也与肿瘤干性和肿瘤耐药等诸多肿瘤恶性行为密切相关,因此有效的抑制EMT的发生将可能极大的有利于肿瘤的治疗。去泛素化酶(deubiquitinating enzymes, DUBs)的主要功能之一就是通过移除底物蛋白质上泛素链,避免其通过泛素蛋白酶体途径降解,来维持细胞内蛋白质水平的动态平衡。去泛素化酶作为调节蛋白质泛素化修饰的一类重要酶类,其异常表达或酶活性的改变通常都会导致疾病的发生。众多研究发现,部分去泛素化酶在肿瘤侵袭和转移过程中表达失衡,在肿瘤转移的过程中扮演着重要的角色。EMT是指由上皮型细胞转变为间质型细胞的动态细胞生物学过程,在该过程中涉及到例如Snial1、Slug、ZEB1等EMT相关转录因子和细胞表面的例如E-钙黏着蛋白、N-钙黏着蛋白等分子标志物表达水平的变化。这些蛋白质通常具有不稳定性,易被降解等特征。EMT过程的发生,涉及到许多蛋白质稳定性的调节,而去泛素化酶作为一类维持蛋白质稳定的重要酶类,在调节这些蛋白质的稳定性方面发挥着重要的作用。EMT的发生也与TGF-β通路、Wnt通路等细胞内众多信号通路的异常活化密不可分,去泛素化酶通过介导这些信号通路的活化,从而间接的调节EMT发生发展。去泛素化酶通过调节EMT相关分子或EMT相关信号通路等多种方式直接或间接影响EMT进展,因此,通过靶向于去泛素化酶抑制肿瘤的侵袭和转移,将为肿瘤治疗提供新的治疗手段和方案,从而有效的推动肿瘤的治疗。本文主要就去泛素化酶在调节EMT相关分子以及信号通路等方面,阐述去泛素化酶在EMT过程中所发挥的重要作用及其作为肿瘤治疗靶点的可能性。     

Sprouty-2对胃癌细胞上皮间质转化及侵袭转移的影响

目的:研究Sprouty2(SPRY2)基因在胃癌肿瘤细胞上皮间质转化(EMT)和侵袭转移的影响。方法:体外培养人胃癌细胞(BGC-823),采用慢病毒介导的sh RNA沉默SPRY2基因,并用实时定量PCR与Western blot检测其SPRY2、E-钙黏蛋白(E-cadherin)、波形蛋白(vimentin)的表达,采用细胞划痕实验、Transwell实验检测SPRY2基因沉默后的胃癌细胞侵袭转移能力变化。结果:在慢病毒介导sh RNA沉默SPRY2基因的人胃癌BGC-823细胞中,SPRY2的m RNA和蛋白表达明显降低(P0.05),SPRY2沉默后人胃癌细胞E-cadherin的蛋白表达增多(P0.05),vimentin的蛋白表达减少(P0.05)。此外,SPRY2沉默后,胃癌细胞迁移能力和侵袭能力明显减弱(P值均P0.05)。结论:Sprouty-2基因通过调节E-cadherin与vimentin的表达参与胃癌细胞的上皮-间质转化,进而促进胃癌细胞的迁移与侵袭。     

miR-155、EMT与肿瘤侵袭转移的研究进展

肿瘤细胞发生上皮间质转化(EMT)是其获得侵袭和转移能力的关键环节之一,而miR-155是EMT的重要调节因子,它通过靶向调节参与这一过程的关键蛋白因子的表达而发挥作用。miR-155的上述功能具有组织和细胞特异性,即在不同的肿瘤组织细胞中它具有促进或抑制侵袭和转移的能力,其功能的发挥取决于其作用靶点的生物学特征。就miR-155与EMT以及肿瘤侵袭转移关系的研究进展作一综述。     

外泌体调控肿瘤侵袭转移的研究进展

外泌体(exosomes)是一种由多种类型细胞分泌的磷脂双层膜囊泡,直径在30～100 nm之间。它们存在于几乎所有体液中,如血液、脑脊液、尿液、胆汁、乳汁等。外泌体能够携带多种物质,介导细胞间通讯并反映来源细胞的状态。外泌体在肿瘤进展中发挥了重要的作用,它们可以通过促进肿瘤细胞上皮-间质转化(epithelial-mesenchymal transition,EMT)、形成转移前微环境(pre-metastatic niche,PMN)以及促进促炎症和免疫抑制微环境的形成,促进肿瘤的侵袭转移。本文综述了外泌体调控肿瘤侵袭转移的作用机制,包括外泌体介导的细胞间信号传递、外泌体调控肿瘤细胞增殖、迁移和侵袭等方面。此外,本文还探讨了外泌体在肿瘤微环境中的作用及其与免疫逃逸的关系,期望为深入研究外泌体对肿瘤的调控作用提供新的思路、为肿瘤治疗提供新的靶点和策略。     

调控肿瘤上皮–间质转化及肿瘤干细胞样特性的信号通路串话

上皮–间质转化（epithelial-mesenchymal transition,EMT）是上皮来源肿瘤细胞获得侵袭和转移能力的重要生物学过程。肿瘤干细胞样细胞（cancer stem-like cells,CSLCs）在肿瘤发生、侵袭、转移和复发中亦起着关键作用。近年发现,EMT与肿瘤干细胞样特性获得存在密切关联,二者通过TGF-β、Wnt/β-catenin、Notch、Hedgehog、FGF、PI3k/Akt等多种信号通路及通路间的信号串话而交互作用,共同影响着肿瘤发生、侵袭及转移,了解调控EMT/CSLCs关键信号分子的功能及相互作用对于肿瘤靶向治疗具有重要意义。     

上皮—间质转化在肾间质纤维化中的作用

上皮－间质转化在发育和纤维化过程中具有重要作用。本文综述了上皮－间质转化发生的过程及其机制的研究进展,尤其是细胞外基质、生长因子、粘附分子及基因对上皮－间质转化的影响。并就在肾间质纤维化过程中因上皮－间质转化致成纤维细胞增多,从而导致肾纤维化的可能作用及其影响因素作一述。     

Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis

The role of various matrix metalloproteinases (MMP)—such as gelatinases, stromelysins, matrilysin, collagenase-3, and membrane-bound MMP (MB-MMP)—in tumor invasion and metastasis is discussed. Data suggesting significance for malignant growth of the expression level of these enzymes and also of their activators and inhibitors are presented. It is concluded that at different stages of tumor progression the activity of different MMPs is displayed, which is regulated by various growth factors and oncogenes. Different malignancies are characterized by changes in activities of specific MMPs. Data are presented which show significance of the ratio between the MMP activity and that of tissue inhibitors of metalloproteinases (TIMP) in tumor invasion and metastasis, especially in connection with a dual role of TIMP as both MMP inhibitors and activators.     

Wnt7a,frequently silenced by CpG methylation,inhibits tumor growth and metastasis via suppressing epithelial-mesenchymal transition in gastric cancer

Wnt7a is a member of the Wnt family and has been reported to be involved in the carcinogenesis and progression of many types of human cancer. However, little is known about Wnt7a expression and function in gastric cancer (GC). In the present study, Wnt7a expression in GC tissues and cells was investigated, the correlation between Wnt7a expression and the prognosis was also examined. The effects of Wnt7a on proliferation, invasion, and metastasis were evaluated in vitro and in vivo. Furthermore, the expression of epithelial-mesenchymal transition (EMT) markers and hypermethylation of the Wnt7a promoter were both detected. Wnt7a was downregulated in GC and its expression was associated with poor prognosis of patients with GC. Moreover, upregulation of Wnt7a significantly suppressed the growth, invasion, and metastasis abilities of GC cells in vitro and in vivo. Mechanistically, Wnt7a was found to inhibit EMT process of GC cells. In addition, the reducing expression of Wnt7a was due to methylation of 5′-CpG island within the promoter. Furthermore, the tumor suppressor role of Wnt7a is independent of canonical Wnt/β-catenin signaling in GC cells. In conclusion, our findings demonstrated that Wnt7a could be used as a potential diagnostic marker and target for GC management.     

胃癌侵袭转移相关基因的研究进展

肿瘤的侵袭转移是恶性肿瘤患者死亡的主要原因。目前对胃癌侵袭转移的分子机制尚未查明。胃癌侵袭转移过程中涉及许多特殊基因,包括促进转移的转移基因和控制转移的转移抑制基因。转移基因有：细胞粘附分子(cAM)基因、基质金属蛋白酶(MMPs)基因、肝素酶(heparanase)基因等;转移抑制基因有：nm23、组织基质金属蛋白酶抑制因子(TIMPs)基因等。本文对胃癌侵袭转移相关基因及其产物的结构、功能及其在侵袭转移过程中作用的研究进展作一综述。     

The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis

Tumor budding occurs at the invasive front of cancer; the tumor cells involved have metastatic and stemness features, indicating a poor prognosis. Tumor budding is partly responsible for cancer metastasis, and its initiation is based on the epithelial-mesenchymal transition (EMT) process. The EMT process involves the conversion of epithelial cells into migratory and invasive cells, and is a profound event in tumorigenesis. The EMT, associated with the formation of cancer stem cells (CSCs) and resistance to therapy, results from a combination of gene mutation, epigenetic regulation, and microenvironmental control. Tumor budding can be taken to represent the EMT in vivo. The EMT process is under the influence of the tumor microenvironment as well as tumor cells themselves. Here, we demonstrate that the tumor microenvironment dominates EMT development and impacts cancer metastasis, as well as promotes CSC formation and mediates drug resistance. In this review, we mainly discuss components of the microenvironment, such as the extracellular matrix (ECM), inflammatory cytokines, metabolic products, and hypoxia, that are involved in and impact on the acquisition of tumor-cell motility and dissemination, the EMT, metastatic tumor-cell formation, tumor budding and CSCs, and cancer metastasis, including subsequent chemo-resistance. From our point of view, the tumor microenvironment now constitutes a promising target for cancer therapy.     

卵巢癌侵袭转移机制的生物信息学研究进展

卵巢癌因其侵袭转移特性,致死率极高,居所有妇科恶性肿瘤之首。近年来随着高通量测序技术及生物信息学方法的快速发展,越来越多调控卵巢癌侵袭转移机制的相关生物大分子被发现。本文对卵巢癌侵袭转移机制的研究背景及现状进行了综述,归纳总结了侵袭转移机制相关调控因素,并对蛋白质组学和单细胞组学的生物信息学分析工具及数据库进行了汇总和介绍,以期为卵巢肿瘤细胞侵袭转移机制的深入研究提供理论依据和科研线索。     

Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment

Every year about 500,000 people in the United States die as a result of cancer. Among them, 90% exhibit systemic disease with metastasis. Considering this high rate of incidence and mortality, it is critical to understand the mechanisms behind metastasis and identify new targets for therapy. In recent years, two broad mechanisms for metastasis have received significant attention: epithelial-to-mesenchymal transition (EMT) and tumor microenvironment interactions. EMT is believed to be a major mechanism by which cancer cells become migratory and invasive. Various cancer cells--both in vivo and in vitro--demonstrate features of epithelial-to-mesenchymal-like transition. In addition, many steps of metastasis are influenced by host contributions from the tumor microenvironment, which help determine the course and severity of metastasis. Here we evaluate the diverse mechanisms of EMT and tumor microenvironment interactions in the progression of cancer, and construct a rational argument for targeting these pathways to control metastasis.     

CD147与肿瘤浸润转移的生物学行为的相互关系

CD147是一种在多种组织细胞膜表面表达的跨膜糖蛋白,通过诱导基质金属蛋白酶(matrix metalloproteinase,M M P)产生,强化胶原蛋白酶水解作用,且可以与整联蛋白(integrin)α3β1和α6β1形成复合体,促进基底膜的降解和肿瘤细胞的移出。另外CD147的过表达促进肿瘤血管内皮生长因子(vascular endothelial growth factor,VEGF)的大量产生,加速肿瘤血管的生成和生长。现在就C D147在肿瘤浸润转移等方面的研究进展作一综述。     

DEDD,a novel tumor repressor,reverses epithelial-mesenchymal transition by activating selective autophagy

Metastasis is the spread of cancer cells from their primary location to other parts of the body. Metastatic cancer is responsible for most cancer deaths. Increasing evidence indicates that epithelial-mesenchymal transition (EMT), a crucial developmental program, contributes to control cancer invasion and metastasis. We recently reported that death effector domain-containing DNA-binding protein (DEDD), a key effector molecule for cell death signaling receptors, attenuates EMT and acts as an endogenous suppressor of tumor growth and metastasis. We found that DEDD physically interacts with the class III PtdIns 3-kinase complex containing PIK3C3 and BECN1, which controls critical aspects of autophagy; this interaction activates autophagy and induces the autophagy-mediated lysosomal degradation of SNAI/Snail and TWIST, two master inducers of the EMT process. Further study reveals that the DEDD-PIK3C3 interaction can support the stability of PIK3C3 to maintain autophagic activity and promote the degradation of SNAI and TWIST. Our finding indicates that DEDD is a prognostic marker and a potential therapeutic target for the prevention and treatment of cancer metastasis. Moreover, regulation of the DEDD-PIK3C3 interaction may serve as an entry point to translate modifiers of this interaction into clinical endpoints.     

DEDD,a novel tumor repressor,reverses epithelial-mesenchymal transition by activating selective autophagy

Metastasis is the spread of cancer cells from their primary location to other parts of the body. Metastatic cancer is responsible for most cancer deaths. Increasing evidence indicates that epithelial-mesenchymal transition (EMT), a crucial developmental program, contributes to control cancer invasion and metastasis. We recently reported that death effector domain-containing DNA-binding protein (DEDD), a key effector molecule for cell death signaling receptors, attenuates EMT and acts as an endogenous suppressor of tumor growth and metastasis. We found that DEDD physically interacts with the class III PtdIns 3-kinase complex containing PIK3C3 and BECN1, which controls critical aspects of autophagy; this interaction activates autophagy and induces the autophagy-mediated lysosomal degradation of SNAI/Snail and TWIST, two master inducers of the EMT process. Further study reveals that the DEDD-PIK3C3 interaction can support the stability of PIK3C3 to maintain autophagic activity and promote the degradation of SNAI and TWIST. Our finding indicates that DEDD is a prognostic marker and a potential therapeutic target for the prevention and treatment of cancer metastasis. Moreover, regulation of the DEDD-PIK3C3 interaction may serve as an entry point to translate modifiers of this interaction into clinical endpoints.